Lifecore Biomedical Inc (LFCR) Stock Price, Quote & News

Company Profile

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 952 368 4300

Website: www.lifecore.com

Address:

3515 Lyman Boulevard, Chaska, United States

11thestate May. 28 at 2:52 PM

Lifecore Biomedical ($LFCR) agreed to settle $3.75 million with investors over claims it misled them about internal controls, inventory management, and financial reporting risks. Investors have until July 7, 2026 to file a claim: https://11th.com/cases/lifecore-investor-settlement

0 · Reply

11thestate May. 22 at 1:58 PM

The $3.75 million Lifecore Biomedical ($LFCR) deadline is July 7, 2026 If you bought shares between October 7, 2020 and March 19, 2024, you are likely eligible for the $ $3.75 million recovery fund. This settlement resolves claims that Lifecore Biomedical misled investors regarding misled investors about internal controls, inventory management, and financial reporting risks. The stock dropped following the disclosure, and now the company is paying back to impacted shareholders ($0.2 per share). File your claim here: https://11th.com/cases/lifecore-investor-settlement

0 · Reply

focafoca99 May. 21 at 11:27 AM

$LFCR plans to attend the William Blair 46th Annual Growth Stock Conference June 2-4, 2026 in Chicago.

0 · Reply

StocktwitsEarnings May. 6 at 11:57 AM

$LFCR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.43 up 18.87% YoY • Reported revenue of $23.19M down -6.12% YoY • Lifecore reaffirmed its 2026 guidance, expecting revenue between $120M and $125M, and Adjusted EBITDA in the range of $20.5M to $25M for calendar year 2026.

0 · Reply

focafoca99 May. 6 at 11:45 AM

$LFCR mentioned its Q1 2026 loss of $15M amid a 34% revenue drop, but reaffirmed full‑year guidance and added three new commercial

0 · Reply

SuperGreenToday Apr. 28 at 3:46 AM

$LFCR Share Price: $5.09 Contract Selected: Dec 18, 2026 $5 Calls Buy Zone: $0.81 – $1.00 Target Zone: $1.35 – $1.65 Potential Upside: 58% ROI Time to Expiration: 234 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

11thestate Apr. 27 at 3:56 PM

The $3.75 million Lifecore Biomedical ($LFCR) deadline is July 7, 2026 If you bought shares between October 7, 2020 and March 19, 2024, you are likely eligible for the $3.75 million recovery fund. This settlement resolves claims that Lifecore Biomedical misled investors regarding internal controls, inventory management, and financial reporting risks. The stock dropped following the disclosure, and now the company is paying back to impacted shareholders ($0.2 per share). File your claim here: https://11th.com/cases/lifecore-investor-settlement

0 · Reply

cfvk Apr. 24 at 7:04 PM

$LFCR didn't quite make it to 6 yet, but was over 5 for a bit.

0 · Reply

WeFindBitcoin Apr. 24 at 4:29 AM

$LFCR In last conference call transcript, CEO mention Alcon deal exact time confirmation is coming up. this alone will re-rate stock to $7.

0 · Reply

WeFindBitcoin Apr. 23 at 2:24 PM

$LFCR add

0 · Reply

Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference

May 12, 2026, 4:05 PM EDT - 18 days ago

Lifecore Biomedical to Participate at CDMO Live Europe

2026-05-07T06:36:02.000Z - 24 days ago

Lifecore reports Q1 EPS (43c), consensus (29c)

May 6, 2026, 8:00 AM EDT - 25 days ago

Lifecore Biomedical Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 25 days ago

Lifecore Biomedical Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 25 days ago

Lifecore Biomedical Quarterly report: Q3 2026

May 6, 2026, 7:05 AM EDT - 25 days ago

Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update

Apr 29, 2026, 4:05 PM EDT - 4 weeks ago

Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026

2026-04-29T12:39:24.000Z - 4 weeks ago

Lifecore price target raised to $6 from $5.50 at Barrington

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Lifecore Biomedical Proxy statement: Proxy filing

Apr 22, 2026, 4:05 PM EDT - 5 weeks ago

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 8, 2026, 8:00 AM EDT - 7 weeks ago

Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit

2026-03-26T11:17:05.000Z - 2 months ago

Lifecore signs two CDMO service agreements with biopharmaceutical customer

Mar 26, 2026, 7:00 AM EDT - 2 months ago

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

2026-03-23T11:28:55.000Z - 2 months ago

Lifecore signs CDMO manufacturing services agreement with aesthetics customer

Mar 23, 2026, 7:00 AM EDT - 2 months ago

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

2026-03-17T13:56:39.000Z - 2 months ago

Lifecore price target lowered to $5 from $8.50 at Stephens

Mar 17, 2026, 9:00 AM EDT - 2 months ago

Lifecore Biomedical Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

2026-03-17T11:41:52.000Z - 2 months ago

Lifecore upgraded to Outperform from Market Perform at Barrington

Mar 16, 2026, 5:56 PM EDT - 2 months ago

Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 16, 2026, 8:30 AM EDT - 2 months ago

Lifecore Biomedical Transcript: Transition period

Mar 16, 2026, 8:30 AM EDT - 2 months ago

Lifecore Biomedical Earnings release: Transition period

Mar 16, 2026, 8:30 AM EDT - 2 months ago

Lifecore Biomedical Slides: Transition period

2026-03-16T12:13:45.000Z - 2 months ago

Lifecore sees ‘modest’ revenue growth in 2027

2026-03-16T12:07:13.000Z - 2 months ago

Lifecore reports Q4 EPS (16c), consensus (16c)

Mar 16, 2026, 8:00 AM EDT - 2 months ago

Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update

Mar 16, 2026, 7:00 AM EDT - 2 months ago

Lifecore Biomedical Slides: Investor presentation

Mar 10, 2026, 4:05 PM EDT - 2 months ago

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum

Mar 9, 2026, 4:05 PM EDT - 2 months ago

Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026

2026-03-04T21:50:14.000Z - 3 months ago

Lifecore, Indomo enter DT-001 development services agreement

Mar 4, 2026, 4:03 PM EST - 3 months ago

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment

Feb 17, 2026, 7:05 AM EST - 3 months ago

Lifecore Biomedical to Participate at DCAT Week 2026

Jan 29, 2026, 5:09 PM EST - 4 months ago

HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Jan 16, 2026, 4:45 PM EST - 4 months ago

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 15, 2026, 10:39 AM EST - 4 months ago

Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights

2025-12-29T10:05:20.000Z - 5 months ago

KeyBanc says momentum, strategic value building at Lifecore

2025-12-18T12:05:53.000Z - 5 months ago

Lifecore to be added to Nasdaq Biotechnology Index

Dec 18, 2025, 7:00 AM EST - 5 months ago

Lifecore Biomedical to be Added to Nasdaq Biotech Index

2025-12-17T12:17:16.000Z - 5 months ago

Lifecore signs CDMO master services agreement with pharma customer

Dec 17, 2025, 7:00 AM EST - 5 months ago

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer

Dec 16, 2025, 7:00 AM EST - 5 months ago

Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference

Nov 20, 2025, 10:00 AM EST - 6 months ago

Lifecore Biomedical Transcript: Stephens Annual Investment Conference

Nov 18, 2025, 4:30 AM EST - 6 months ago

Lifecore Biomedical Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 4:05 PM EST - 7 months ago

Lifecore Biomedical to Participate in Upcoming Investor Conferences

Nov 6, 2025, 4:30 PM EST - 7 months ago

Lifecore Biomedical Earnings Call Transcript: Q1 2026

Nov 6, 2025, 4:30 PM EST - 7 months ago

Lifecore Biomedical Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Lifecore Biomedical Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 7 months ago

Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 7 months ago

Lifecore Biomedical Quarterly report: Q1 2026

Oct 30, 2025, 4:05 PM EDT - 7 months ago

Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025

2025-10-29T11:27:45.000Z - 7 months ago

Lifecore signs agreement with leading global pharmaceutical company

Oct 29, 2025, 7:00 AM EDT - 7 months ago

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

Oct 28, 2025, 7:00 AM EDT - 7 months ago

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market

Oct 13, 2025, 7:00 AM EDT - 8 months ago

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

Sep 23, 2025, 8:00 AM EDT - 8 months ago

Lifecore Biomedical Registration statement: Registration filing

Sep 18, 2025, 8:00 AM EDT - 9 months ago

Lifecore Biomedical Proxy statement: Proxy filing

Sep 9, 2025, 4:50 PM EDT - 9 months ago

Lifecore Biomedical Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 4:05 PM EDT - 9 months ago

Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference

Aug 12, 2025, 7:00 AM EDT - 10 months ago

Lifecore Biomedical Slides: Investor Presentation

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Lifecore Biomedical Earnings Call Transcript: Q4 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Lifecore Biomedical Annual report: Q4 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Lifecore Biomedical Earnings release: Q4 2025

Aug 7, 2025, 4:05 PM EDT - 10 months ago

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Jul 31, 2025, 4:05 PM EDT - 10 months ago

Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

Jun 12, 2025, 7:00 AM EDT - 1 year ago

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

May 27, 2025, 7:00 AM EDT - 1 year ago

Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer

Apr 22, 2025, 7:00 AM EDT - 1 year ago

Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference

11thestate May. 28 at 2:52 PM

0 · Reply

11thestate May. 22 at 1:58 PM

0 · Reply

focafoca99 May. 21 at 11:27 AM

$LFCR plans to attend the William Blair 46th Annual Growth Stock Conference June 2-4, 2026 in Chicago.

0 · Reply

StocktwitsEarnings May. 6 at 11:57 AM

0 · Reply

focafoca99 May. 6 at 11:45 AM

$LFCR mentioned its Q1 2026 loss of $15M amid a 34% revenue drop, but reaffirmed full‑year guidance and added three new commercial

0 · Reply

SuperGreenToday Apr. 28 at 3:46 AM

0 · Reply

11thestate Apr. 27 at 3:56 PM

0 · Reply

cfvk Apr. 24 at 7:04 PM

$LFCR didn't quite make it to 6 yet, but was over 5 for a bit.

0 · Reply

WeFindBitcoin Apr. 24 at 4:29 AM

$LFCR In last conference call transcript, CEO mention Alcon deal exact time confirmation is coming up. this alone will re-rate stock to $7.

0 · Reply

WeFindBitcoin Apr. 23 at 2:24 PM

$LFCR add

0 · Reply

WeFindBitcoin Apr. 14 at 4:54 AM

$PAR this one looks cheaper in number, but I think risk/reward ratio in $LFCR is better, highly likely 2X return in 12 months.

0 · Reply

cfvk Apr. 13 at 7:19 PM

$LFCR holding some 3.6s and 3.7s, would like to see 6-7 again. seems to be finally bottomed and bouncing

1 · Reply

WeFindBitcoin Apr. 10 at 4:06 PM

$LFCR somebody is been accumulating shares

0 · Reply

WeFindBitcoin Apr. 10 at 1:01 PM

$LFCR Trump’s pharmaceutical tariffs have shifted from ‘move production out of China’ to ‘make it only in the U.S.’ LFCR will be signing more deals in the upcoming months.

0 · Reply

focafoca99 Apr. 8 at 7:59 PM

$LFCR is another conference notice, this time for the American Biomanufacturing Summit.

0 · Reply

utahstock12 Apr. 6 at 5:56 PM

$LFCR what happened at noon here?

1 · Reply

InvestwithMEH Apr. 2 at 12:45 AM

Finding the next Runner: micro-cap stocks riding mega-trends $SYPR $OPXS $CTM $PPSI $LFCR https://open.substack.com/pub/jlgas2023/p/finding-the-next-runner-micro-cap?r=1t0tw1&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

1 · Reply

WeFindBitcoin Mar. 31 at 3:14 PM

$LFCR

0 · Reply

cfvk Mar. 31 at 2:53 PM

$LFCR saw a 99k bid, probably fake

0 · Reply

11thestate Mar. 26 at 1:48 PM

$LFCR investors — there's no hidden secret here. Just one thing you really need to know. Here's how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/lifecore-investor-settlement

0 · Reply

DARKP00L Mar. 26 at 11:13 AM

$LFCR 07:12 on Mar. 26 2026 Lifecore Expands Manufacturing Deal With Existing Pharma Client #tradeideas

0 · Reply

PLATINUM_TRADES Mar. 25 at 2:36 PM

$LFCR This is more than $4.22 I told u.. Nice pop🚨🚨

0 · Reply

Market Cap	188.30M
Revenue (ttm)	128.87M
Net Income (ttm)	-38.72M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-30.05%
Debt to Equity Ratio	7.11

Volume	149,800
Avg Vol	308,280
Day's Range	N/A - N/A
Shares Out	37.51M
Stochastic %K	86%
Beta	1.08
Analysts	Sell
Price Target	$6.67